{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06445075",
            "orgStudyIdInfo": {
                "id": "SRK-015-006"
            },
            "organization": {
                "fullName": "Scholar Rock, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese",
            "officialTitle": "A Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apitegromab in Overweight and Obese Adult Subjects",
            "acronym": "EMBRAZE",
            "therapeuticArea": [
                "Endocrinology"
            ],
            "study": "efficacy-and-safety-of-apitegromab-for-the-treatment-of-adults-who-are-overweight-or-obese"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-21",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-10-20",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-22",
            "studyFirstSubmitQcDate": "2024-05-30",
            "studyFirstPostDateStruct": {
                "date": "2024-06-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Scholar Rock, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 agonist therapy in subjects with overweight or obesity",
            "detailedDescription": "This phase 2 randomized, double-blind, placebo-controlled, multicenter study will assess the safety, efficacy, and pharmacokinetics (PK) of apitegromab when used as an adjunctive therapy to GLP-1 agonist therapy in subjects with overweight and obesity and without diabetes. Each subject will receive either semaglutide or tirzepatide, depending upon availability, and will maintain that course throughout the treatment period. In addition, all subjects will be randomized 1:1 to receive either apitegromab or placebo during the treatment period."
        },
        "conditionsModule": {
            "conditions": [
                "Overweight and Obesity"
            ],
            "keywords": [
                "Overweight",
                "Obesity"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Parallel Assignment",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "maskingDescription": "Active treatment, randomized, double-blind, placebo-controlled",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1",
                    "type": "EXPERIMENTAL",
                    "description": "Apitegromab + incretin mimetic",
                    "interventionNames": [
                        "Drug: Apitegromab",
                        "Drug: Semaglutide",
                        "Drug: Tirzepatide"
                    ]
                },
                {
                    "label": "Cohort 2",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo + incretin mimetic",
                    "interventionNames": [
                        "Drug: Placebo",
                        "Drug: Semaglutide",
                        "Drug: Tirzepatide"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Apitegromab",
                    "description": "Apitegromab (SRK-015) is a fully human anti-proMyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab will be administered every 4 weeks by intravenous (IV) infusion.",
                    "armGroupLabels": [
                        "Cohort 1"
                    ],
                    "otherNames": [
                        "SRK-015"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Same appearance and composition as apitegromab drug product but does not contain the active ingredient. Placebo will be administered every 4 weeks by intravenous (IV) infusion.",
                    "armGroupLabels": [
                        "Cohort 2"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Semaglutide",
                    "description": "Glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide will be administered every week by subcutaneous injection.",
                    "armGroupLabels": [
                        "Cohort 1",
                        "Cohort 2"
                    ],
                    "otherNames": [
                        "WEGOVY"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Tirzepatide",
                    "description": "Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide will be administered every week by subcutaneous injection.",
                    "armGroupLabels": [
                        "Cohort 1",
                        "Cohort 2"
                    ],
                    "otherNames": [
                        "ZEPBOUND"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change from Baseline in total Lean Body Mass (kg) at 24 weeks",
                    "description": "Dual-energy X-ray absorptiometry will be used to evaluate body composition",
                    "timeFrame": "Baseline and 24 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change from Baseline in body weight",
                    "description": "Total body weight will be assessed via a calibrated scale",
                    "timeFrame": "Baseline and 24 weeks"
                },
                {
                    "measure": "Change from Baseline in percent lean body mass (%)",
                    "description": "Dual-energy X-ray absorptiometry will be used to evaluate body composition",
                    "timeFrame": "Baseline and 24 weeks"
                },
                {
                    "measure": "Change from Baseline in fat body mass (kg and %)",
                    "description": "Dual-energy X-ray absorptiometry will be used to evaluate body composition",
                    "timeFrame": "Baseline and 24 weeks"
                },
                {
                    "measure": "Change from Baseline in visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and trunk fat body mass (kg and %)",
                    "description": "Dual-energy X-ray absorptiometry will be used to evaluate body composition",
                    "timeFrame": "Baseline and 24 weeks"
                },
                {
                    "measure": "Percent (%) of weight loss from baseline due to fat body mass loss",
                    "description": "Dual-energy X-ray absorptiometry will be used to evaluate body composition",
                    "timeFrame": "Baseline and 24 weeks"
                },
                {
                    "measure": "Percent (%) of weight loss from baseline due to lean body mass loss",
                    "description": "Dual-energy X-ray absorptiometry will be used to evaluate body composition",
                    "timeFrame": "Baseline and 24 weeks"
                },
                {
                    "measure": "Concentration of apitegromab in circulation over time",
                    "description": "Blood samples will be assessed for circulating concentration of apitegromab",
                    "timeFrame": "Baseline up to 40 weeks"
                },
                {
                    "measure": "Concentration of latent myostatin in circulation over time",
                    "description": "Blood samples will be assessed for circulating concentration of latent myostatin",
                    "timeFrame": "Baseline up to 24 weeks"
                },
                {
                    "measure": "Treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)",
                    "description": "Incidence and severity of TEAEs and SAEs",
                    "timeFrame": "Baseline up to 40 weeks"
                },
                {
                    "measure": "Presence of anti-drug antibodies (ADA) against apitegromab over time",
                    "description": "Measured in serum blood samples",
                    "timeFrame": "Baseline up to 40 weeks"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Change from Baseline in HbA1c",
                    "description": "Blood samples will be assessed for HbA1c (glycated hemoglobin)",
                    "timeFrame": "Baseline up to 32 weeks"
                },
                {
                    "measure": "Change from baseline in fasting serum triglycerides",
                    "description": "Blood samples will be assessed for fasting serum triglycerides",
                    "timeFrame": "Baseline up to 32 weeks"
                },
                {
                    "measure": "Change from baseline in total cholesterol",
                    "description": "Blood samples will be assessed for total cholesterol",
                    "timeFrame": "Baseline up to 32 weeks"
                },
                {
                    "measure": "Change from baseline in low-density lipoprotein cholesterol (LDL-C)",
                    "description": "Blood samples will be assessed low-density lipoprotein cholesterol (LDL-C)",
                    "timeFrame": "Baseline up to 32 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria\n\n* Able to comprehend the informed consent process and provide written informed consent prior to study enrollment and the conduct of any study-related assessments to study enrollment and the conduct of any study-related assessments\n* Male or female, age \u2265 18 and \u2264 65 years at the time of informed consent\n* Stable body weight (\u00b15 kg) within 90 days of Screening\n* At Screening, a BMI of:\n\n  1. \u226530.0 kg/m2 to \u226445.0 kg/m2 or\n  2. \u226527.0 kg/m2 to \\<30.0 kg/m2 with the presence of 1 or more weight-related comorbid condition(s). Note: See exclusion criteria for specific organ class disease parameters\n\nExclusion Criteria:\n\n* History of or active cardiovascular, neurovascular, peripheral vascular, pulmonary, hepatic, pancreatic, neuromuscular, and/or psychiatric disease\n* Active malignancy, other than local subcutaneous squamous cell and basal cell carcinomas\n* History of immunosuppressive, chemotherapeutic, or radiation treatment within 12 months prior to Screening\n* History of Type 1 diabetes or active Type 2 diabetes (T2D). If there was a history of T2D and it resolved, then the resolution must have occurred \\>12 months prior to Screening. Prediabetes managed with nonpharmacologic approaches (exercise and diet) is not an exclusion",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Scholar Rock, Inc. Clinical Trials Administration",
                    "role": "CONTACT",
                    "phone": "857-259-3860",
                    "email": "clinicaltrials@scholarrock.com"
                }
            ],
            "locations": [
                {
                    "facility": "ProSciento CRU",
                    "status": "RECRUITING",
                    "city": "Chula Vista",
                    "state": "California",
                    "zip": "91911",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.64005,
                        "lon": -117.0842
                    }
                },
                {
                    "facility": "AdventHealth Translational Research Institute",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32804",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Great Lakes Clinical Trials, LLC d/b/a Flourish Research",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60640",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "Tandem Clinical Research GI, LLC",
                    "status": "RECRUITING",
                    "city": "Marrero",
                    "state": "Louisiana",
                    "zip": "70072",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.89937,
                        "lon": -90.10035
                    }
                },
                {
                    "facility": "Apex Mobile Clinical Research",
                    "status": "RECRUITING",
                    "city": "Bellaire",
                    "state": "Texas",
                    "zip": "77401",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.70579,
                        "lon": -95.45883
                    }
                },
                {
                    "facility": "Clinical Trials of Texas, LLC dba Flourish Research",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000050177",
                    "term": "Overweight"
                }
            ],
            "ancestors": [
                {
                    "id": "D000044343",
                    "term": "Overnutrition"
                },
                {
                    "id": "D000009748",
                    "term": "Nutrition Disorders"
                },
                {
                    "id": "D000001835",
                    "term": "Body Weight"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12701",
                    "name": "Obesity",
                    "relevance": "LOW"
                },
                {
                    "id": "M26186",
                    "name": "Overweight",
                    "asFound": "Overweight",
                    "relevance": "HIGH"
                },
                {
                    "id": "M25307",
                    "name": "Overnutrition",
                    "relevance": "LOW"
                },
                {
                    "id": "M12684",
                    "name": "Nutrition Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5114",
                    "name": "Body Weight",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000591245",
                    "term": "Semaglutide"
                },
                {
                    "id": "C000629749",
                    "term": "Tirzepatide"
                }
            ],
            "ancestors": [
                {
                    "id": "D000097789",
                    "term": "Glucagon-Like Peptide-1 Receptor Agonists"
                },
                {
                    "id": "D000007004",
                    "term": "Hypoglycemic Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000054795",
                    "term": "Incretins"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M9043",
                    "name": "Glucagon",
                    "relevance": "LOW"
                },
                {
                    "id": "M26997",
                    "name": "Glucagon-Like Peptide 1",
                    "relevance": "LOW"
                },
                {
                    "id": "M353561",
                    "name": "Semaglutide",
                    "asFound": "Stretching",
                    "relevance": "HIGH"
                },
                {
                    "id": "M204206",
                    "name": "Tirzepatide",
                    "asFound": "DISKUS",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M3401",
                    "name": "Glucagon-Like Peptide-1 Receptor Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M27905",
                    "name": "Incretins",
                    "relevance": "LOW"
                },
                {
                    "id": "M8866",
                    "name": "Gastric Inhibitory Polypeptide",
                    "relevance": "LOW"
                },
                {
                    "id": "M10054",
                    "name": "Hypoglycemic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                }
            ]
        }
    },
    "hasResults": false
}